z-logo
Premium
Development of an ultra‐performance liquid chromatography‐electrospray ionization‐Orbitrap mass spectrometry method for determination of xanthopurpurin in rat plasma and its application to pharmacokinetic study
Author(s) -
Han Deen,
Shi Yanmei,
Tian Ping,
Wei Hengchao,
Miao Mingsan,
Li Xiumin
Publication year - 2020
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.4838
Subject(s) - chemistry , chromatography , formic acid , electrospray ionization , mass spectrometry , liquid chromatography–mass spectrometry , extraction (chemistry) , high performance liquid chromatography , electrospray , orbitrap , pharmacokinetics , tandem mass spectrometry , analytical chemistry (journal) , pharmacology , medicine
A rapid and sensitive method was developed and validated for the quantitative determination of xanthopurpurin (XPP) in rat plasma using ultra‐performance liquid chromatography‐electrospray ionization‐Orbitrap mass spectrometry. XPP inhibits IgE production and prevents peanut‐induced anaphylaxis. The XPP and emodin (internal standard) were determined in negative ion mode with m/z 239.0350 → 211.0400 and 269.0455 → 241.0507, respectively. The separation process was achieved using an ACQUITY UPLC HSS T 3 column with acetonitrile and 0.1% formic acid in water (85:15). The linear range was 0.5–100 ng/mL, and the correlation coefficient ( r 2 ) was > 0.993. The inter‐day and intra‐day precision was within an acceptable range of 15%. The extraction recovery and matrix effect were 78.9–87.2% and 94.3–98.5%, respectively. Under different conditions, the XPP was stable in the range of 5.6–10.6%. This method was successfully applied to study the pharmacokinetics of XPP with an oral dose of 10.0 mg/kg and intravenous dose of 2.0 mg/kg in rats. The absolute oral bioavailability of XPP was 4.6%.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here